Aspergillosis TrustPost date: 3 Jul 2018 - 9:38am
Wednesday, July 18, 2018 - 13:13Slide presentation
Wednesday, July 18, 2018 - 13:10Slide presentation
Wednesday, July 18, 2018 - 13:05Slide presentation
Wednesday, July 18, 2018 - 13:02Slide presentation
In this study, we investigated the role of Aspergillus proteases—which contribute to the pathogenesis of Aspergillus-induced diseases such as allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, and atopic asthma—and their mechanisms of action in airway inflammation using primary human bronchial epithelial cells, and evaluated the inflammatory responses mediated by mitochondrial ROS. We found that Aspergillus proteases regulated the expression of multifunctional inflammatory cytokines such as interleukin (IL)−1β, −6, and −8, and transforming growth factor (TGF)-β, w...
Publication date: March 2018Source: Journal de Mycologie Médicale, Volume 28, Issue 1Author(s): M.-P. Ledoux, J. Denis, Y. Nivoix, R. HerbrechtAbstractIsavuconazole, the active moiety of its prodrug isavuconazonium, is a new extended-spectrum triazole whose activity against yeasts, molds, including Aspergillus and mucorales, and dimorphic fungi has been shown in vitro and in preclinical models. The most relevant pharmacokinetics features are water-solubility of the prodrug, rapid cleavage of the prodrug into active moiety and cleavage product by plasmatic esterases, high oral bioavailability of isavuconazole with an...
Publication date: March 2018Source: Journal de Mycologie Médicale, Volume 28, Issue 1Author(s): J. Denis, M.-P. Ledoux, Y. Nivoix, R. HerbrechtAbstractTriazoles compounds are first-line agents for the treatment of invasive fungal diseases. Isavuconazole is the most recent triazole compound, approved in 2015 by the FDA and the EMA to treat invasive aspergillosis and mucormycosis. We reviewed here the in vitro activity of isavuconazole against a vast spectrum of species. Isavuconazole MICs were evaluated using CLSI, EUCAST or Etest methods, with no significant differences between the technics. Low MIC50 and MIC90 (
Publication date: September 2018Source: Medical Mycology Case Reports, Volume 21Author(s): Jessica D. Workum, Suzanne W. de Jong, Mark S. Gresnigt, Katharina L. Becker, Peter Pickkers, Frank L. van de Veerdonk, Yvonne F. Heijdra, Eva KolwijckAbstractInvasive pulmonary aspergillosis is increasingly described in non-neutropenic patients, such as patients with COPD receiving corticosteroids and the critically ill. Here, we present a case of a lethal pulmonary Aspergillus niger infection in a COPD patient. Immunological tests showed an impaired innate and adaptive immune response to Aspergillus. A history of COPD, unresponsive...